Clinical trial
Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer
NCT02569242 · Ono Pharmaceutical Co. Ltd, Industry · Completed
Key facts
| NCT number | NCT02569242 |
|---|---|
| Title | Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer |
| Official title | ONO-4538 Phase III Study A Multicenter, Randomized, Open-label Study in Patients With Esophageal Cancer Refractory or Intolerant to Combination Therapy With Fluoropyrimidine and Platinum-based Drugs |
| Lead sponsor | Ono Pharmaceutical Co. Ltd, Industry |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Esophageal Cancer |
| Intervention type | Drug |
| Interventions | Nivolumab, Docetaxel/Paclitaxel |
| Enrollment | 419 |
| Start date | Dec 14, 2015 |
| Primary completion | Oct 23, 2020 |
| Completion | Oct 23, 2020 |
| First posted | Oct 6, 2015 |
| Last update posted | Jul 6, 2022 |
| Countries | Denmark, Germany, Italy, Japan, South Korea, Taiwan, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: